 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"CAPTOPRIL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mCAPTOPRIL[0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mCAPTOPRIL[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Captopril information"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"captopril"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CAPTOPRIL: description: DESCRIPTION Captopril and hydrochlorothiazide tablets, USP for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. Captopril, [0m
[31mthe first of a new class of antihypertensive agents, is a specific competitive inhibitor of angiotensin I-converting enzyme [0m[1;31m([0m[31mACE[0m[1;31m)[0m[31m, the enzyme responsible for the conversion of angiotensin I to [0m
[31mangiotensin II. Hydrochlorothiazide is a benzothiadiazide [0m[1;31m([0m[31mthiazide[0m[1;31m)[0m[31m diuretic-antihypertensive. Captopril, USP is a white to off-white crystalline powder with characteristic sulfide-like odor; it is [0m
[31mfreely soluble in water, ethanol, methanol, chloroform, isopropyl alcohol and methylene chloride and soluble in ethyl acetate. It dissolves in dilute solution of alkali hydroxide. CAPTOPRIL: [0m
[31mdescription: Hydrochlorothiazide, USP is a white or almost white, almost odorless crystalline powder. Very slightly soluble in water, sparingly soluble in Ethanol and Methanol, soluble in Acetone. [0m
[31mFreely soluble in N,N-Dimethylformamide, in n-Butylamine and in diluted solutions of alkali hydroxides. Practically insoluble in Ether, in Chloroform and in diluted mineral acids. Captopril is [0m
[31mdesignated chemically as [0m[1;31m1[0m[31m-[0m[1;31m[[0m[1;31m([0m[31m2S[0m[1;31m)[0m[1;31m-3[0m[31m-Mercapto-[0m[1;31m2[0m[31m-methylpropionyl[0m[1;31m][0m[31m-L-proline; Hydrochlorothiazide is [0m[1;31m6[0m[31m-Chloro-[0m[1;31m3[0m[31m,[0m[1;31m4[0m[31m-dihydro-[0m[1;31m2[0m[31m H [0m[1;31m-1[0m[31m,[0m[1;31m2[0m[31m,[0m[1;31m4[0m[31m-benzothiadiazine-[0m[1;31m7[0m[31m-sulfonamide [0m[1;31m1[0m[31m,[0m[1;31m1[0m[31m-dioxide. CAPTOPRIL: description: [0m
[31mTheir structural formulas are: Captopril and hydrochlorothiazide tablets are available for oral administration in four combinations of captopril with hydrochlorothiazide: [0m[1;31m25[0m[31m mg with [0m[1;31m15[0m[31m mg, [0m[1;31m25[0m[31m mg with [0m
[1;31m25[0m[31m mg, [0m[1;31m50[0m[31m mg with [0m[1;31m15[0m[31m mg, and [0m[1;31m50[0m[31m mg with [0m[1;31m25[0m[31m mg. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, croscarmellose sodium, magnesium [0m
[31mstearate, microcrystalline cellulose, pregelatinized starch [0m[1;31m([0m[31mcorn[0m[1;31m)[0m[31m and sodium lauryl sulfate. The [0m[1;31m25[0m[31m mg/[0m[1;31m25[0m[31m mg and [0m[1;31m50[0m[31m mg/[0m[1;31m25[0m[31m mg tablets also contain FD&C Yellow No. [0m[1;31m6[0m[31m Aluminum Lake. CAPTOPRIL: [0m
[31mdescription: captopril-struct         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: information_for_patients: INFORMATION FOR PATIENTS Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema [0m[1;31m([0m[31me.g., swelling [0m
[31mof face, eyes, lips, tongue, larynx and extremities; difficulty in swallowing or breathing; hoarseness[0m[1;31m)[0m[31m and to discontinue therapy. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal [0m
[31mAngioedema .[0m[1;31m)[0m[31m Patients should be told to report promptly any indication of infection [0m[1;31m([0m[31me.g., sore throat, fever[0m[1;31m)[0m[31m, which may be a sign of neutropenia, or of progressive edema which might be related to [0m
[31mproteinuria and nephrotic syndrome. All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. [0m
[31mOther causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician. CAPTOPRIL: information_for_patients: [0m
[31mPatients should be advised not to use potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes without consulting their physician. [0m[1;31m([0m[31mSee PRECAUTIONS: General and Drug[0m
[31mInteractions: Captopril ; ADVERSE REACTIONS: Captopril .[0m[1;31m)[0m[31m Patients should be warned against interruption or discontinuation of medication unless instructed by the physician. Heart failure patients on [0m
[31mcaptopril therapy should be cautioned against rapid increases in physical activity. Patients should be informed that captopril and hydrochlorothiazide tablets should be taken one hour before meals [0m
[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: overdosage: OVERDOSAGE Captopril : Correction of hypotension would be of primary concern. Volume expansion with an intravenous infusion of normal saline is the treatment of choice [0m
[31mfor restoration of blood pressure. While captopril may be removed from the adult circulation by hemodialysis, there is inadequate data concerning the effectiveness of hemodialysis for removing it from[0m
[31mthe circulation of neonates or children. Peritoneal dialysis is not effective for removing captopril; there is no information concerning exchange transfusion for removing captopril from the general [0m
[31mcirculation. Hydrochlorothiazide : In addition to the expected diuresis, overdosage of thiazides may produce varying degrees of lethargy which may progress to coma within a few hours, with minimal [0m
[31mdepression of respiration and cardiovascular function and without evidence of serum electrolyte changes or dehydration. The mechanism of thiazide-induced CNS depression is unknown. Gastrointestinal [0m
[31mirritation and hypermotility may occur. CAPTOPRIL: overdosage: Transitory increase in BUN has been reported, and serum electrolyte changes may occur, especially in patients with impaired renal [0m
[31mfunction. In addition to gastric lavage and supportive therapy for stupor or coma, symptomatic treatment of gastrointestinal effects may be needed. The degree to which hydrochlorothiazide is removed [0m
[31mby hemodialysis has not been clearly established. Measures as required to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function should be instituted.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: spl_product_data_elements: CAPTOPRIL AND HYDROCHLOROTHIAZIDE CAPTOPRIL AND HYDROCHLOROTHIAZIDE CAPTOPRIL CAPTOPRIL HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE ANHYDROUS LACTOSE SILICON[0m
[31mDIOXIDE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN SODIUM LAURYL SULFATE R;[0m[1;31m27[0m[31m CAPTOPRIL AND HYDROCHLOROTHIAZIDE CAPTOPRIL AND HYDROCHLOROTHIAZIDE CAPTOPRIL [0m
[31mCAPTOPRIL HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE ANHYDROUS LACTOSE SILICON DIOXIDE CROSCARMELLOSE SODIUM MAGNES CAPTOPRIL: spl_product_data_elements: IUM STEARATE CELLULOSE, MICROCRYSTALLINE SODIUM [0m
[31mLAURYL SULFATE FD&C YELLOW NO. [0m[1;31m6[0m[31m STARCH, CORN Peach R;[0m[1;31m28[0m[31m CAPTOPRIL AND HYDROCHLOROTHIAZIDE CAPTOPRIL AND HYDROCHLOROTHIAZIDE CAPTOPRIL CAPTOPRIL HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE ANHYDROUS [0m
[31mLACTOSE SILICON DIOXIDE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN SODIUM LAURYL SULFATE R;[0m[1;31m29[0m[31m CAPTOPRIL AND HYDROCHLOROTHIAZIDE CAPTOPRIL AND HYDROCHLOROTHIAZIDE[0m
[31mCAPTOPRIL CAPTOPRIL HYDROCHLOR CAPTOPRIL: spl_product_data_elements: OTHIAZIDE HYDROCHLOROTHIAZIDE ANHYDROUS LACTOSE SILICON DIOXIDE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE CELLULOSE, [0m
[31mMICROCRYSTALLINE SODIUM LAURYL SULFATE FD&C YELLOW NO. CAPTOPRIL: spl_product_data_elements: [0m[1;31m6[0m[31m STARCH, CORN Peach R;[0m[1;31m30[0m[31m         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: indications_and_usage: INDICATIONS & USAGE Captopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. The blood pressure lowering effects of [0m
[31mcaptopril and thiazides are approximately additive. This fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components. When captopril[0m
[31mand hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough [0m[1;31m([0m[31mbefore the next dose[0m[1;31m)[0m[31m. Also, with such a [0m
[31mcombination, a daily dose of [0m[1;31m15[0m[31m mg of hydrochlorothiazide may be adequate. Treatment may, therefore, be initiated with captopril and hydrochlorothiazide tablets [0m[1;31m25[0m[31m mg/[0m[1;31m15[0m[31m mg once daily. CAPTOPRIL: [0m
[31mindications_and_usage: Subsequent titration should be with additional doses of the components [0m[1;31m([0m[31mcaptopril, hydrochlorothiazide[0m[1;31m)[0m[31m as single agents or as captopril and hydrochlorothiazide tablets [0m[1;31m50[0m[31m mg/[0m[1;31m15[0m
[31mmg, [0m[1;31m25[0m[31m mg/[0m[1;31m25[0m[31m mg, or [0m[1;31m50[0m[31m mg/[0m[1;31m25[0m[31m mg [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. In using captopril and hydrochlorothiazide, consideration should be given to the risk of neutropenia/agranulocytosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mCaptopril and hydrochlorothiazide may be used for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen [0m
[31mvascular disease, captopril and hydrochlorothiazide should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to[0m
[31mother drug combinations. CAPTOPRIL: indications_and_usage: ACE inhibitors [0m[1;31m([0m[31mfor which adequate data are available[0m[1;31m)[0m[31m cause a higher rate of angioedema in black than in non-black patients [0m[1;31m([0m[31msee WARNINGS: [0m
[31mCaptopril: Head and Neck Angioedema and Intestinal Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: general_precautions: General : Captopril : Impaired Renal Function : Some patients with renal disease, particularly those with severe renal artery stenosis, have developed [0m
[31mincreases in BUN and serum creatinine after reduction of blood pressure with captopril. Captopril dosage reduction and/or discontinuation of diuretic may be required. For some of these patients, it [0m
[31mmay not be possible to normalize blood pressure and maintain adequate renal perfusion [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY , DOSAGE AND ADMINISTRATION , ADVERSE REACTIONS: Altered Laboratory Findings [0m[1;31m)[0m[31m. [0m
[31mHyperkalemia : Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including captopril. CAPTOPRIL: general_precautions: When treated with ACE inhibitors, [0m
[31mpatients at risk for the development of hyperkalemia include those with: renal insufficiency; diabetes mellitus; and those using concomitant potassium-sparing diuretics, potassium supplements or [0m
[31mpotassium-containing salt substitutes; or other drugs associated with increases in serum potassium. [0m[1;31m([0m[31mSee PRECAUTIONS: Information for Patients and Drug Interactions: Captopril ; ADVERSE REACTIONS: [0m
[31mAltered Laboratory Findings .[0m[1;31m)[0m[31m Cough : Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always [0m
[31mresolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough. Surgery/Anesthesia : In patients undergoing major surgery or during[0m
[31manesthesia with agents that produce hypotension, captopril will block angiotensin II formation secondary to compensatory renin release. CAPTOPRIL: general_precautions: If hypotension occurs and is [0m
[31mconsidered to be due to this mechanism, it can be corrected by volume expansion. Hemodialysis : Recent clinical observations have shown an association of hypersensitivity-like [0m[1;31m([0m[31manaphylactoid[0m[1;31m)[0m[31m [0m
[31mreactions during hemodialysis with high-flux dialysis membranes [0m[1;31m([0m[31me.g., AN69[0m[1;31m)[0m[31m in patients receiving ACE inhibitors as medication. In these patients, consideration should be given to using a different [0m
[31mtype of dialysis membrane or a different class of medication. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Anaphylactoid Reactions During Membrane Exposure [0m[1;31m)[0m[31m. Hydrochlorothiazide : Periodic determination of serum [0m
[31melectrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. All patients receiving thiazide therapy should be observed for clinical signs of fluid or [0m
[31melectrolyte imbalance, namely: hyponatremia, hypochloremic alkalosis, and hypokalemia. CAPTOPRIL: general_precautions: Serum and urine electrolyte determinations are particularly important when the [0m
[31mpatient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance may include: dryness of mouth, thirst, weakness, lethargy, drowsiness, [0m
[31mrestlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Hypokalemia may develop, especially with [0m
[31mbrisk diuresis, or when severe cirrhosis is present. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia can sensitize or exaggerate the response of the[0m
[31mheart to the toxic effects of digitalis [0m[1;31m([0m[31me.g., increased ventricular irritability[0m[1;31m)[0m[31m. Because captopril reduces the production of aldosterone, concomitant therapy with captopril reduces the [0m
[31mdiuretic-induced hypokalemia.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: warnings: [0m[1;31m)[0m[31m Fetal/Neonatal Morbidity and Mortality : ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have [0m
[31mbeen reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. The use of ACE inhibitors during the second and third trimesters of [0m
[31mpregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also [0m
[31mbeen reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic [0m
[31mlung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor [0m
[31mexposure. CAPTOPRIL: warnings: These adverse effects do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and [0m
[31mfetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of [0m
[31mcaptopril as soon as possible. Rarely [0m[1;31m([0m[31mprobably less often than once in every thousand pregnancies[0m[1;31m)[0m[31m, no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised[0m
[31mof the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intraamniotic environment. If oligohydramnios is observed, captopril should be [0m
[31mdiscontinued unless it is considered life-saving for the mother. Contraction stress testing [0m[1;31m([0m[31mCST[0m[1;31m)[0m[31m, a non-stress test [0m[1;31m([0m[31mNST[0m[1;31m)[0m[31m, or biophysical profiling [0m[1;31m([0m[31mBPP[0m[1;31m)[0m[31m may be appropriate, depending upon the week [0m
[31mof pregnancy. CAPTOPRIL: warnings: Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Infants with histories[0m
[31mof in utero exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and [0m
[31mrenal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. While captopril may be removed from the adult [0m
[31mcirculation by hemodialysis, there is inadequate data concerning the effectiveness of hemodialysis for removing it from the circulation of neonates or children. Peritoneal dialysis is not effective [0m
[31mfor removing captopril; there is no information concerning exchange transfusion for removing captopril from the general circulation. When captopril was given to rabbits at doses about [0m[1;31m0[0m[31m. CAPTOPRIL: [0m
[31mwarnings: [0m[1;31m8[0m[31m to [0m[1;31m70[0m[31m times [0m[1;31m([0m[31mon a mg/kg basis[0m[1;31m)[0m[31m the maximum recommended human dose, low incidences of craniofacial malformations were seen. No teratogenic effects of captopril were seen in studies of [0m
[31mpregnant rats and hamsters. On a mg/kg basis, the doses used were up to [0m[1;31m150[0m[31m times [0m[1;31m([0m[31min hamsters[0m[1;31m)[0m[31m and [0m[1;31m625[0m[31m times [0m[1;31m([0m[31min rats[0m[1;31m)[0m[31m the maximum recommended human dose. Hepatic Failure : Rarely, ACE Inhibitors [0m
[31mhave been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and [0m[1;31m([0m[31msometimes[0m[1;31m)[0m[31m death. The mechanism of this syndrome is not understood. [0m
[31mPatients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up. Hydrochlorothiazide : [0m
[31mThiazides should be used with caution in severe renal disease. CAPTOPRIL: warnings: In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in [0m
[31mpatients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte [0m
[31mbalance may precipitate hepatic coma. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic [0m
[31mlupus erythematosus has been reported. In general, lithium should not be given with diuretics [0m[1;31m([0m[31msee PRECAUTIONS: Drug Interactions: Hydrochlorothiazide [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: adverse_reactions: ADVERSE REACTIONS Captopril : Reported incidences are based on clinical trials involving approximately [0m[1;31m7000[0m[31m patients. Renal : About one of [0m[1;31m100[0m[31m patients developed[0m
[31mproteinuria [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Each of the following has been reported in approximately [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m of [0m[1;31m1000[0m[31m patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, [0m
[31mnephrotic syndrome, polyuria, oliguria, and urinary frequency. Hematologic : Neutropenia/agranulocytosis has occurred [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cases of anemia, thrombocytopenia, and pancytopenia have been [0m
[31mreported. Dermatologic : Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about [0m[1;31m4[0m[31m to [0m[1;31m7[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients, usually [0m
[31mduring the first four weeks of therapy. CAPTOPRIL: adverse_reactions: It is usually maculopapular, and rarely urticarial. The rash is usually mild and disappears within a few days of dosage reduction,[0m
[31mshort-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. Pruritus, without rash, occurs in about [0m[1;31m2[0m[31m of [0m[1;31m100[0m[31m patients. Between [0m
[1;31m7[0m[31m and [0m[1;31m10[0m[31m percent of patients with skin rash have shown eosinophilia and/or positive ANA titers. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported. Flushing [0m
[31mor pallor has been reported in [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m of [0m[1;31m1000[0m[31m patients. Cardiovascular : Hypotension may occur; see WARNINGS and PRECAUTIONS [0m[1;31m([0m[31mDrug Interactions[0m[1;31m)[0m[31m for discussion of hypotension with captopril therapy. [0m
[31mTachycardia, chest pain, and palpitations have each been observed in approximately [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. CAPTOPRIL: adverse_reactions: Angina pectoris, myocardial infarction, Raynaudâ€™s syndrome, and [0m
[31mcongestive heart failure have each occurred in [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m of [0m[1;31m1000[0m[31m patients. Dysgeusia : Approximately [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients developed a diminution or loss of taste [0m
[31mperception. Taste impairment is reversible and usually self-limited [0m[1;31m([0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m months[0m[1;31m)[0m[31m even with continued drug administration. Weight loss may be associated with the loss of taste. Angioedema : [0m
[31mAngioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in [0m[1;31m1000[0m[31m patients. Angioedema involving the upper airways has caused[0m
[31mfatal airway obstruction. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal Angioedema and PRECAUTIONS: Information for Patients [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Captopril is an antihypertensive medication that combines with hydrochlorothiazide to treat hypertension. It is a specific competitive inhibitor of angiotensin I-converting enzyme [0m[1;32m([0m[32mACE[0m[1;32m)[0m[32m, [0m
[32mresponsible for converting angiotensin I to angiotensin II. Hydrochlorothiazide is a thiazide diuretic-antihypertensive. Captopril is available in different combinations with hydrochlorothiazide for [0m
[32moral administration. Patients should be advised to report any signs of angioedema or infection and to avoid potassium supplements without consulting their physician. Overdosage of captopril primarily [0m
[32mrequires correction of hypotension, and while it can be removed from the adult circulation by hemodialysis, its effectiveness in neonates or children is not well-established. Captopril is indicated [0m
[32mfor the treatment of hypertension and may be used as initial therapy or substituted for previously titrated doses of the individual components. It should be used with caution in patients with impaired[0m
[32mrenal function or those at risk for hyperkalemia. ACE inhibitors like captopril have been associated with fetal and neonatal morbidity and death when administered to pregnant women and should be [0m
[32mdiscontinued as soon as pregnancy is detected. Adverse reactions to captopril can include renal issues, hematologic changes, dermatologic reactions, cardiovascular effects, dysgeusia, and angioedema.[0m

[32mSOURCE: CAPTOPRIL label[0m
[32mEXTRACT_START_END: DESCRIPTION Captopril and hydrochlorothiazide tablets [0m[32m...[0m[32m with any medicine.[0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Captopril is an antihypertensive medication that combines with [0m
[34mhydrochlorothiazide to treat hypertension. It is a specific competitive inhibitor of angiotensin I-converting enzyme [0m[1;34m([0m[34mACE[0m[1;34m)[0m[34m, responsible for converting angiotensin I to angiotensin II. [0m
[34mHydrochlorothiazide is a thiazide diuretic-antihypertensive. Captopril is available in different combinations with hydrochlorothiazide for oral administration. Patients should be advised to report any[0m
[34msigns of angioedema or infection and to avoid potassium supplements without consulting their physician. Overdosage of captopril primarily requires correction of hypotension, and while it can be [0m
[34mremoved from the adult circulation by hemodialysis, its effectiveness in neonates or children is not well-established. Captopril is indicated for the treatment of hypertension and may be used as [0m
[34minitial therapy or substituted for previously titrated doses of the individual components. It should be used with caution in patients with impaired renal function or those at risk for hyperkalemia. [0m
[34mACE inhibitors like captopril have been associated with fetal and neonatal morbidity and death when administered to pregnant women and should be discontinued as soon as pregnancy is detected. Adverse [0m
[34mreactions to captopril can include renal issues, hematologic changes, dermatologic reactions, cardiovascular effects, dysgeusia, and angioedema.[0m

[34mSOURCE: CAPTOPRIL label[0m
[34mEXTRACT_START_END: DESCRIPTION Captopril and hydrochlorothiazide tablets [0m[34m...[0m[34m with any medicine.[0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe information provided by FDAHandler regarding Captopril does not [0m
[32mdirectly answer the question about the risk of hospitalization. The FDA label for Captopril includes details about its use as an antihypertensive medication, its mechanism of action as an ACE [0m
[32minhibitor, and various precautions and potential adverse reactions associated with its use. However, there is no explicit mention of the risk of hospitalization as a result of taking Captopril.[0m

[32mGiven that Captopril is used to treat hypertension and may prevent complications associated with high blood pressure, it could potentially reduce the risk of hospitalization due to [0m
[32mhypertension-related issues when used appropriately. However, adverse reactions such as renal issues, hematologic changes, dermatologic reactions, cardiovascular effects, dysgeusia, and angioedema [0m
[32mcould, in some cases, lead to hospitalization if they are severe.[0m

[32mSince the FDA label data does not specify the risk of hospitalization associated with Captopril use, my final answer must be DO-NOT-KNOW. The degree of risk for hospitalization due to either the [0m
[32mtherapeutic effects or adverse reactions of Captopril cannot be determined from the information provided.[0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler for information regarding Captopril."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided details about Captopril's use, mechanism of action, and potential adverse reactions."[0m[32m,[0m
[32m      [0m[32m"The information from FDAHandler did not directly address the risk of hospitalization associated with Captopril use."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CAPTOPRIL increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler for information regarding Captopril."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided details about Captopril's use, mechanism of action, and potential adverse reactions."[0m[34m,[0m
[34m      [0m[34m"The information from FDAHandler did not directly address the risk of hospitalization associated with Captopril use."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CAPTOPRIL increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler for information regarding Captopril.[0m
[1;31m2[0m[31m. FDAHandler provided details about Captopril's use, mechanism of action, and potential adverse reactions.[0m
[1;31m3[0m[31m. The information from FDAHandler did not directly address the risk of hospitalization associated with Captopril use.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label data for Captopril does not specify information about the risk of hospitalization associated with its use. Therefore, it is not possible to determine whether Captopril increases or [0m
[32mdecreases the risk of hospitalization based on the available FDA label information.[0m
